P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
NCT04960579
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this study, doctors tested a new treatment for people with a type of cancer called Multiple Myeloma who didn't get better after other treatments. They used special cells from another person and raised the dose slowly to see how well it worked.
In this study, doctors tested a new treatment for people with a type of cancer called Multiple Myeloma who didn't get better after other treatments. They used special cells from another person and raised the dose slowly to see how well it worked.
Third Opinion AI Generated Synopsis
Trial Summary
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
